Over-ten-year follow-up studies, including neoadjuvant trials with single-agent PD-1 blockade, finally reveal the prospect of long-term outcomes in advanced staged melanoma following ICI treatments (21, 22). The gene discussed is PDCD1; the disease is melanoma.